Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several food/food-timing and grapefruit juice interaction claims are not supported by the provided label excerpts, while the statement that LIPITOR may be taken with or without food is directly supported. Claims about dairy/CYP3A4 and calcium binding are not supported, and numeric claims (e.g., peak levels ~30% drop; grapefruit juice 2–3x) are not provided in the supplied label.
Category Scores
Accurate Statements
Lipitor can be taken with or without food.
Supported by Label 2.1: "LIPITOR can be administered as a single dose at any time of the day, with or without food."
Unsupported Statements
Lipitor (atorvastatin) absorption is minimally impacted by dairy.
No provided label excerpt addresses dairy specifically or quantifies dairy effects on absorption.
Food in general, including dairy products like milk or cheese, reduces the rate but not the overall extent of absorption of atorvastatin.
No provided label excerpt describes rate vs extent of absorption with food; only LDL-C reduction is similar with or without food (Label 12.3).
Peak plasma levels of atorvastatin drop by about 30% with food.
No numeric pharmacokinetic change or peak-level statement is provided in the supplied label excerpts.
The area under the curve (total exposure) of atorvastatin stays the same with food.
No AUC numeric/constancy statement is provided in the supplied label excerpts.
Calcium-rich foods bind to some drugs, but Lipitor does not chelate significantly with calcium.
No provided label excerpt discusses calcium binding/chelation effects with calcium-rich foods.
Unlike bile acid sequestrants (e.g., cholestyramine), statins like Lipitor tolerate food.
No provided label excerpt compares statins to bile acid sequestrants regarding food tolerance.
Dairy might slightly delay the onset of atorvastatin action but will not meaningfully lower cholesterol reduction.
No dairy-specific timing/onset statement is provided; label only states LDL-C reduction is similar with or without food (Label 12.3), without discussing onset.
No evidence shows dairy blunts long-term LDL lowering.
The supplied label excerpts do not address dairy and long-term LDL lowering.
No direct interaction reduces Lipitor efficacy from dairy.
No dairy-specific interaction information is provided in the supplied label excerpts.
Grapefruit juice increases atorvastatin levels about 2-3 times by inhibiting CYP3A4.
Label 7.2 states grapefruit juice can increase plasma concentrations of atorvastatin (especially with excessive intake), but no 2–3x numeric factor is provided in the supplied excerpts.
Increased atorvastatin levels from grapefruit juice risk muscle damage.
The supplied label excerpts establish that strong CYP3A4 inhibitors increase risk of myopathy/rhabdomyolysis, and grapefruit juice can increase plasma concentrations (Label 7.2), but they do not explicitly link grapefruit juice to muscle damage in the provided text.
Dairy carries no enzyme effect related to CYP3A4 inhibition for atorvastatin.
No provided label excerpt addresses dairy effects on CYP3A4 or enzyme inhibition.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
If the question is about food effects on atorvastatin pharmacokinetics (rate/AUC/peak levels) or food-specific interactions (e.g., dairy), the supplied label excerpts do not include those details; an on-label response would need to rely on the label-supported statement that "LDL-C reduction is similar whether LIPITOR is given with or without food" (Label 12.3), rather than providing numeric PK changes.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some claims about grapefruit juice and muscle damage include unsupported numeric and causal details relative to the supplied label excerpts. However, the label does support that grapefruit juice can increase atorvastatin plasma concentrations and that increased concentrations with certain CYP3A4 inhibitors can raise myopathy/rhabdomyolysis risk; the provided excerpts do not explicitly confirm grapefruit-juice-to-muscle-damage linkage or quantify the magnitude.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple food/dairy and grapefruit juice claims include numeric PK values or mechanistic specificity not present in the provided label excerpts.
Suggested Improvement
Limit on-label food statements to what is in the supplied label: (1) dosing administration can be with or without food (Label 2.1) and (2) LDL-C reduction is similar with or without food (Label 12.3). For grapefruit, state that it can increase atorvastatin plasma concentrations (Label 7.2) and avoid unsupported numeric multipliers and explicit muscle-damage risk unless the provided label text directly supports that linkage.